Table 1 Baseline demographic and clinical characteristics of the study cohort
From: Genetic architecture of cardiometabolic risks in people living with HIV
Variable | PLWHEAa n = 3095 (%) | PLWHAAb n = 3189 (%) | Total N = 6284 (%) | p valuec |
|---|---|---|---|---|
Age | 53.36 ± 9.70 | 53.18 ± 10.70 | 53.27 ± 10.22 | 0.49 |
Gender |  |  |  | < 0.0001 |
 Male | 2763 (89.3) | 2199 (69.0) | 4962 (79.0) |  |
 Female | 332 (10.7) | 990 (31.0) | 1322 (21.0) |  |
Site |  |  |  | < 0.0001 |
 University of Alabama | 744 (24.0) | 882 (27.7) | 1626 (25.9) |  |
 Johns Hopkins | 135 (4.4) | 845 (26.5) | 980 (15.6) |  |
 University of Washington | 623 (20.1) | 261 (8.2) | 884 (14.1) |  |
 University of California San Diego | 640 (20.7) | 187 (5.9) | 827 (13.2) |  |
 Case Western Reserve University | 314 (10.1) | 494 (15.5) | 808 (12.9) |  |
 University of North Carolina | 161 (5.2) | 368 (11.5) | 529 (8.4) |  |
 Fenway | 309 (10.0) | 45 (1.4) | 354 (5.6) |  |
 University of California San Francisco | 169 (5.5) | 107 (3.4) | 276 (4.4) |  |
Type 2 diabetesd | 388 (12.5) | 676 (21.2) | 1064 (16.9) | < 0.0001 |
Myocardial infarctione | 53 (1.7) | 64 (2.0) | 117 (1.9) | < 0.39 |
CD4 countsc | 399 ± 283.5 | 331 ± 277.3 | 364 ± 282.4 | < 0.0001 |
Presence of antiretroviral therapy | 2841 (91.8) | 2823 (88.5) | 5664 (90.1) | < 0.0001 |